INDV stock news today

Supernus confirms special cash dividend for former Indivior stockholders

Supernus said it will pay a special cash dividend to people who previously held Indivior shares. The payment follows the companies' earlier arrangement.

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

Indivior Posts Q3 2026 Results

The drugmaker published its earnings for the July-to-September period of 2026. The filing details how the business performed during those months.

Indivior keeps FY2026 revenue forecast at $1.295B-$1.365B

Indivior Pharmaceuticals left its 2026 full-year revenue outlook unchanged, spanning $1.295 billion to $1.365 billion. That range brackets the $1.334 billion consensus figure.

Indivior Q3 profit tops forecast; revenue also ahead of estimates

Indivior's third-quarter adjusted earnings came in above analyst expectations, and revenue was higher than projected. Both figures exceeded the consensus estimates.

Barclays keeps Overweight rating on Indivior, lifts price target to $45

Barclays stayed positive on Indivior Pharmaceuticals and raised its price target to $45. The rating and target are analyst views on the stock.

Indivior declares $8.13 per share special dividend tied to Supernus merger

Indivior will pay a special cash dividend of $8.13 per share if its merger with Supernus closes. The payout is set for about November 6 to shareholders on record as of October 30.

Indivior ends Reckitt Benckiser supply deal for Suboxone and Subutex tablets early

Indivior is ending its copacker supply agreement with Reckitt Benckiser for Suboxone and Subutex tablets early, moving the termination date to January 15, 2027. The company says it has found a new supplier.

What is the latest news on INDV?

Nov 6, 2026: Supernus confirms special cash dividend for former Indivior stockholders (Fiscal.ai) · Nov 4, 2026: Indivior Pharmaceuticals, Inc. filed an insider trading report (Form 4) (SEC) · Oct 29, 2026: Indivior Posts Q3 2026 Results (Fiscal.ai)

What has INDV filed with the SEC recently?

Nov 4, 2026: Indivior Pharmaceuticals, Inc. filed an insider trading report (Form 4)